Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Leukemia & Lymphoma|June 30, 2004
The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemiaMeletios Dimopoulos, Dimitra Gika, Konstantinos Zervas, et al.
Leukemia & Lymphoma|September 13, 2006
Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosisMeletios Athanasios Dimopoulos, Anastasia Pouli, Athanasios Anagnostopoulos, et al.
Clinical Lymphoma & Myeloma|January 19, 2007
Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatmentAthanasios Anagnostopoulos, Konstantinos Zervas, Marie Kyrtsonis, et al.
European Journal of Haematology|September 30, 2005
Multiple myeloma in elderly patients: prognostic factors and outcomeAthanasios Anagnostopoulos, Dimitra Gika, Argyris Symeonidis, et al.
Pharmacogenomics|October 22, 2016
Correlation of SIN3A genomic variants with β-hemoglobinopathies disease severity and hydroxyurea treatment efficacyAikaterini Gravia, Vasiliki Chondrou, Alexandra Kolliopoulou, et al.
Pharmacogenomics|February 20, 2016
Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patientsConstantina Chalikiopoulou, Anastasia-Gerasimoula Tavianatou, Argyro Sgourou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamideMeletios Athanasios Dimopoulos, Athanasios Anagnostopoulos, Marie-Christine Kyrtsonis, et al.
Hematological Oncology|August 22, 2018
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study GroupSotirios G Papageorgiou, Christos K Kontos, Ioannis Kotsianidis, et al.
Leukemia Research|May 8, 2010
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)Efstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hadjiharissi, et al.
Therapeutic Advances in Hematology|December 21, 2020
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromesSotirios G Papageorgiou, Ioannis Kotsianidis, Anthi Bouchla, et al.
Pageof 2